Personal profile
Personal profile
As Cancer Center Director at Fox Chase Cancer Center, Jonathan Chernoff works with Temple University Health System and Temple University peers to lead Fox Chase into the future of cancer care. With decades of research expertise, Chernoff has helped Fox Chase focus on the areas that best leverage the institution’s enhanced strengths in scientific development: translational research, precision medicine, epigenetics, signaling reprograming, immunotherapy, hematologic malignancies, and cancer disparities.
A molecular oncologist and board-certified medical oncologist, Chernoff joined Fox Chase in 1991. In addition to helping define the strategic direction for Fox Chase research, he has made fundamental contributions in his own laboratory, which focuses on factors that control cell growth and movement, including oncogenes and anticancer or tumor-suppressor genes. He currently holds the Stanley P. Reimann Chair in Oncology Research. Chernoff has trained dozens of postdoctoral and graduate students at Fox Chase. He serves as an adjunct professor for the Drexel University School of Medicine and for the University of Pennsylvania, and is a member of the Cancer Signaling and Epigenetics research program at Fox Chase.
In addition to these roles, Chernoff has served on multiple external advisory boards, including the Scientific Advisory Board for Nexgenix Pharmaceuticals, as well as advisory boards for Genentech, Novartis Pharmaceuticals, and the New York University (Perlmutter) Cancer Center, among others. He has also taken on roles for multiple committees and programs within Fox Chase.
Chernoff earned his bachelor’s degree in molecular biophysics and biochemistry from Yale College and his medical degree and doctorate from the Mount Sinai School of Medicine in New York. He completed his residency in internal medicine at the University Health Center of Pittsburgh and a clinical fellowship in medical oncology at Johns Hopkins Oncology Center. He then held a postdoctoral fellowship in cellular and developmental biology at Harvard University before coming to Fox Chase.
Research interests
External positions
Scientific Advisory Board, Novo Nordisk
Jan 1 2019 → Dec 31 2020
External Advisory Board, University of Miami Epigenetics
Jan 1 2017 → …
Scientific Advisory Board, Tarsa
Jan 1 2013 → Dec 31 2017
External Advisory Board, Case Western Cancer Signaling Program
Jan 1 2012 → Dec 31 2014
Scientific Advisory Board, Pharma-Arava
Jan 1 2012 → Dec 31 2017
Co-Chair, NF2 Preclinical consortium
Jan 1 2011 → Dec 31 2012
External Advisory Board, NYU Cancer Institute
Jan 1 2011 → Dec 31 2016
Advisory Board, Genentech
Jan 1 2008 → Dec 31 2013
Advisory Board, Novartis Pharmaceuticals
Jan 1 2008 → Dec 31 2011
Adjunct Professor, Drexel University School of Medicine
Jan 1 2004 → …
Scientific Advisory Board, Nexgenix Pharmaceuticals
Jan 1 2004 → Dec 31 2011
Adjunct Assistant Professor, University of Pennsylvania
Jan 1 1996 → …
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Identifying and Targeting Key Driver Genes for Collagen Production within the 11q13/14 Breast Cancer Amplicon
Araiza-Olivera, D., Prudnikova, T. Y., Uribe-Alvarez, C., Cai, K. Q., Franco-Barraza, J., Dones, J. M., Raines, R. T. & Chernoff, J., May 2 2025, In: Molecular Cancer Research. 23, 5, p. 405-415 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation
Budagyan, K., Cannon, A. C., Chatoff, A., Benton, D., Kurimchak, A. M., Araiza-Olivera, D., Gerasimova, A., Snyder, N. W., Duncan, J. S., Uribe-Alvarez, C. & Chernoff, J., Apr 22 2025, In: Cell Reports. 44, 4, p. 115444 115444.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
PAK1 regulates oligodendroglial proliferation and repopulation in homeostatic and demyelinating brain
Wang, Y., Kim, B., Shi, X., Chen, H., Park, J., Zhu, M., Wong, E. M., Park, A. Y., Chernoff, J. & Guo, F., Jun 28 2025, In: Cellular and Molecular Life Sciences. 82, 1, 260.Research output: Contribution to journal › Article › peer-review
Open Access -
PAK2-driven cytoskeleton–endosome dynamics control macrophage hyperphagia and SIRPA engagement
La Rochelle, J. D., Cassidy, J. P., Chernoff, J. & Knaus, U. G., Nov 18 2025, In: Proceedings of the National Academy of Sciences of the United States of America. 122, 46, p. e2516025122 e2516025122.Research output: Contribution to journal › Article › peer-review
Open Access -
Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO)
Dobrzhanskyi, O., Kopetskyi, V., Ross, E. A., Chernoff, J., Shudrak, Y., Kolesnyk, A., Pepenin, M., Horodetskyi, A., Melnitchouk, N. & Kondratskyi, Y., Jun 30 2025, In: Journal of Gastrointestinal Oncology. 16, 3, p. 909-921 13 p.Research output: Contribution to journal › Article › peer-review
Open Access
Prizes
-
Elected Fellow of the American Association for the Advancement of Science
Chernoff, J. (Recipient), 2017
Prize: Honorary award
-
Press/Media
-
Temple Health names new director for Fox Chase Cancer Center
03/19/26
1 item of Media coverage
Press/Media
-
Fox Chase Cancer Center hires COO away from Jefferson's Kimmel Cancer Center
02/3/26
1 item of Media coverage
Press/Media
-
Fox Chase Cancer Center COO departs to lead new organization backed by Nike founder Phil Knight
01/27/26
1 item of Media coverage
Press/Media
-
Temple Health launches national search for new Fox Chase Cancer Center director
Chernoff, J., Uzzo, R. G. & Wiest, D.
10/13/25
1 item of Media coverage
Press/Media
-
Tipoffs: Personnel Changes in Public Policy Organizations, Colleges, Government Agencies - Oct. 10, 2025
Chernoff, J., Uzzo, R. G. & Wiest, D.
10/12/25
1 item of Media coverage
Press/Media